Literature DB >> 2648867

A controlled trial of desipramine in 18 men with posttraumatic stress disorder.

C Reist1, C D Kauffmann, R J Haier, C Sangdahl, E M DeMet, A Chicz-DeMet, J N Nelson.   

Abstract

Eighteen male U.S. veterans meeting DSM-III criteria for posttraumatic stress disorder (PTSD) completed a 4-week double-blind, crossover study comparing administration of 200 mg/day of desipramine with placebo. Response was measured by using the Beck Depression Inventory, the Hamilton Rating Scale for Depression, the Hamilton Rating Scale for Anxiety, and the Impact of Event Scale. Overall, the only apparent response to desipramine was in some symptoms of depression; there were no changes in anxiety and other PTSD symptoms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2648867     DOI: 10.1176/ajp.146.4.513

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  17 in total

1.  A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder.

Authors:  D G Baker; B I Diamond; G Gillette; M Hamner; D Katzelnick; T Keller; T A Mellman; E Pontius; M Rosenthal; P Tucker
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

2.  Posttraumatic Stress Disorder and Acute Stress Disorder II: Considerations for Treatment and Prevention.

Authors:  Shawn P Cahill; Kristin Pontoski; Carla M D'Olio
Journal:  Psychiatry (Edgmont)       Date:  2005-09

3.  Screening antidepressants in the chick separation-stress paradigm.

Authors:  Matthew W Feltenstein; Kenneth J Sufka
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

4.  Posttraumatic Stress Disorder: an integrated overview and neurobiological rationale for pharmacology.

Authors:  Benjamin Kelmendi; Thomas G Adams; Steven Southwick; Chadi G Abdallah; John H Krystal
Journal:  Clin Psychol (New York)       Date:  2017-07-18

Review 5.  Post-traumatic stress disorder in women: epidemiological and treatment issues.

Authors:  Soraya Seedat; Dan J Stein; Paul D Carey
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

6.  Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence.

Authors:  Ismene L Petrakis; Elizabeth Ralevski; Nitigna Desai; Louis Trevisan; Ralitza Gueorguieva; Bruce Rounsaville; John H Krystal
Journal:  Neuropsychopharmacology       Date:  2011-11-16       Impact factor: 7.853

7.  Enhancing clinical trial design of interventions for posttraumatic stress disorder.

Authors:  Andrew C Leon; Lori L Davis
Journal:  J Trauma Stress       Date:  2009-12

Review 8.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

Review 9.  Pharmacotherapy in post-traumatic stress disorder: evidence from randomized controlled trials.

Authors:  Gregory M Sullivan; Yuval Neria
Journal:  Curr Opin Investig Drugs       Date:  2009-01

Review 10.  SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations.

Authors:  Gregory M Asnis; Shari R Kohn; Margaret Henderson; Nicole L Brown
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.